补肾壮骨中药抗骨质疏松有效成分及其药理作用研究进展(1)
[摘要]补肾中药防治骨质疏松症的机制已成为近年来的研究热点，研究发现其具有促进成骨细胞增殖，抑制破骨细胞活性，调节雌激素水平及其受体，促进MSCs成骨并抑制其成脂，调节OPG/RANK/RANKL系统和钙磷代谢及抗氧化等作用。该文从分子和细胞生物学角度对补肾中药抗骨质疏松有效成分及其药理作用机制进行了总结，为揭示其治疗骨质疏松症的机制，深入研究开发补肾壮骨类中药提供参考。
[关键词]补肾中药;骨质疏松;发病机制;药理作用机制;研究进展
Research progress on anti-osteoporotic active ingredients and pharmacological
action mechanism of traditional Chinese kidney-tonifying and
bone-strengthening drugs
, http://www.100md.com
LI Ye1，2， TONG Jie/1， ZHOU Yan-jing/1， XU Xiao-yu1*
(1.College of Pharmaceutical Sciences， Institute of Chinese Medicine， the Key Subject Constructing
Units of Pharmacology of Chinese Materia Medica by the State Administrative Bureau of Traditional Chinese Medicine，Southwest University， Chongqing 400716， China; 2.Department of Clinical Pharmacy of the
First People′s Hospital， Yunnan Province， Kunming 650032， China)
, 百拇医药
[Abstract]The therapeutic effects and mechanisms of traditional Chinese kidney-tonifying drugs in treating osteoporosis have become the focus under study. Pharmacological studies have shown that traditional Chinese kidney-tonifying drugs are promoters for the proliferation of osteoblasts， inhibitors for the activity of osteoclasts， regulators for the estrogen level and its receptor， plays important roles in promoting osteogenesis and suppressing adipogenesis of marrow mesenchymal stem cells (MSCs)， modulating the function of OPG/RANK/RANKL system and the metabolism of calcium and phosphorus， as well as antioxidation. The anti-osteoporotic active ingredients and pharmacological action mechanism of traditional Chinese kidney-tonifying drugs are summarized from the perspective of molecular and cell biology in this paper， so as to provide references for the study of their mechanism of anti-osteoporosis and for the development of traditional Chinese kidney-tonifying and bone-strengthening drugs.
, http://www.100md.com
[Key words]traditional Chinese kidney-tonifying drug; osteoporosis; pathogenesis; pharmacological mechanism; research progress
doi：10.4268/cjcmm20150610
骨质疏松症(osteoporosis，OP)是一种以骨量低下，骨微结构破坏，导致骨脆性增加，易发生骨折为特征的全身性代谢性骨病，以中老年妇女为多见[1]。骨质疏松发病机制复杂，与衰老、激素调控、基因遗传、细胞因子、物理、营养和生活习惯等多因素相关。祖国医学认为，本病主要为肝肾虚衰致使筋骨失养，肾虚是骨质疏症的主要病机[2]，因而中药以补肾壮骨类为主。现代药理研究表明，补益肝肾可调节内分泌状态[3]、增强细胞和体液免疫功能[4]、防止氧自由基过量产生[5]，使骨密度增加，骨抗弯曲和抗压缩能力增强，骨小梁显微结构破坏等表现得到改善和修复，从而达到防治骨质疏松症的目的。补肾壮骨中药在促进成骨与抑制破骨、改善骨髓间充质干细胞骨向与脂向分化平衡失调、促进性激素和细胞因子分泌、对抗细胞氧化应激与调节钙磷代谢等方面发挥积极作用。本文对补肾壮骨类中药抗骨质疏松有效成分及药理作用研究进展作一综述，为进一步阐明“肾主骨”理论的科学内涵以及补肾壮骨类中药的合理开发与应用提供参考。, 百拇医药(李烨 童杰 周衍晶 徐晓玉)
[关键词]补肾中药;骨质疏松;发病机制;药理作用机制;研究进展
Research progress on anti-osteoporotic active ingredients and pharmacological
action mechanism of traditional Chinese kidney-tonifying and
bone-strengthening drugs
, http://www.100md.com
LI Ye1，2， TONG Jie/1， ZHOU Yan-jing/1， XU Xiao-yu1*
(1.College of Pharmaceutical Sciences， Institute of Chinese Medicine， the Key Subject Constructing
Units of Pharmacology of Chinese Materia Medica by the State Administrative Bureau of Traditional Chinese Medicine，Southwest University， Chongqing 400716， China; 2.Department of Clinical Pharmacy of the
First People′s Hospital， Yunnan Province， Kunming 650032， China)
, 百拇医药
[Abstract]The therapeutic effects and mechanisms of traditional Chinese kidney-tonifying drugs in treating osteoporosis have become the focus under study. Pharmacological studies have shown that traditional Chinese kidney-tonifying drugs are promoters for the proliferation of osteoblasts， inhibitors for the activity of osteoclasts， regulators for the estrogen level and its receptor， plays important roles in promoting osteogenesis and suppressing adipogenesis of marrow mesenchymal stem cells (MSCs)， modulating the function of OPG/RANK/RANKL system and the metabolism of calcium and phosphorus， as well as antioxidation. The anti-osteoporotic active ingredients and pharmacological action mechanism of traditional Chinese kidney-tonifying drugs are summarized from the perspective of molecular and cell biology in this paper， so as to provide references for the study of their mechanism of anti-osteoporosis and for the development of traditional Chinese kidney-tonifying and bone-strengthening drugs.
, http://www.100md.com
[Key words]traditional Chinese kidney-tonifying drug; osteoporosis; pathogenesis; pharmacological mechanism; research progress
doi：10.4268/cjcmm20150610
骨质疏松症(osteoporosis，OP)是一种以骨量低下，骨微结构破坏，导致骨脆性增加，易发生骨折为特征的全身性代谢性骨病，以中老年妇女为多见[1]。骨质疏松发病机制复杂，与衰老、激素调控、基因遗传、细胞因子、物理、营养和生活习惯等多因素相关。祖国医学认为，本病主要为肝肾虚衰致使筋骨失养，肾虚是骨质疏症的主要病机[2]，因而中药以补肾壮骨类为主。现代药理研究表明，补益肝肾可调节内分泌状态[3]、增强细胞和体液免疫功能[4]、防止氧自由基过量产生[5]，使骨密度增加，骨抗弯曲和抗压缩能力增强，骨小梁显微结构破坏等表现得到改善和修复，从而达到防治骨质疏松症的目的。补肾壮骨中药在促进成骨与抑制破骨、改善骨髓间充质干细胞骨向与脂向分化平衡失调、促进性激素和细胞因子分泌、对抗细胞氧化应激与调节钙磷代谢等方面发挥积极作用。本文对补肾壮骨类中药抗骨质疏松有效成分及药理作用研究进展作一综述，为进一步阐明“肾主骨”理论的科学内涵以及补肾壮骨类中药的合理开发与应用提供参考。, 百拇医药(李烨 童杰 周衍晶 徐晓玉)